The Latest Cardiac and Vascular News
CAMBRIDGE, England–(BUSINESS WIRE)–PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD. The trial has been designed to improve understanding of the pathobiology of atherosclerotic cardiovascular diseases (ACVD) and how
CAMBRIDGE, England–(BUSINESS WIRE)–PlaqueTec Ltd. has relocated its existing coronary plasma bank from Royal Papworth Hospital to the communal laboratory facility within the Babraham Research Campus in Cambridge. The company has also expanded its headquarters and device development facilities, which are now […]
CAMBRIDGE, England–(BUSINESS WIRE)–PlaqueTec announced today that it will sponsor the exclusive Vulnerable Patient Meeting (VPM), taking place 24-26 June in Stresa, Italy, for the fourth time. VPM, hosted by Cardialysis, is an annual invitation-only meeting focused on atherosclerosis for approximately […]
CAMBRIDGE, England–(BUSINESS WIRE)–Researchers from PlaqueTec Ltd. presented data suggesting that localised coronary inflammation may be independent of systemic elevation of inflammatory biomarkers such as high-sensitivity C reactive protein (hsCRP). The data, presented at the 86th European Atherosclerosis Society (EAS) Congress in […]
CAMBRIDGE, England, January 3, 2018 /PRNewswire/ — Article in JACC: Basic to Translational Science Validates Feasibility and Unique Potential of LBS to Detect Biomarkers for Coronary Artery Disease PlaqueTec today announced the publication of the first peer-reviewed article demonstrating the feasibility […]
CAMBRIDGE, England, November 13, 2017 /PRNewswire/ — The Board of Directors of PLAQUETEC LTD (‘PlaqueTec’) today announced the appointment of Annalisa Jenkins, MBBS, FRCP, as the company’s Chief Executive Officer. Dr. Jenkins, most recently CEO of U.S.-based Dimension Therapeutics, will lead the […]
